Is China Poised to Overtake the US as Biotech's Global Powerhouse?

What was once the United States' unquestioned domain is now China's fastest-rising frontier. China's biotech sector is reshaping the global industry. Big pharma companies are deepening ties with Chinese biotechs, clinical trials are growing at record speed, and patent activity is surging. With all these milestones, is China poised to dethrone the United States as the benchmark for biotech innovation and market leadership? Let's find out.

- Ayesha Siddiqui

China has reached a major milestone in global pharmaceutical innovation. According to the latest report from Clarivate, Mainland China Biopharma Innovation 2.0: From rapid growth to quality-driven development, the country became the world's second-largest source of first launches of new molecular entities (NMEs) in 2024, with an 18 per cent share. The analysis, now in its seventh year, states that China’s biopharmaceutical sector has moved from the Innovation 1.0 period into an Innovation 2.0 phase focused on steady, quality-focused development and wider global recognition.

A separate report from L.E.K. Consulting and PharmaDJ, Advancing Innovation and Global Reach: The Next Chapter in China’s Clinical Trial Development, finds that China’s clinical trial volume has reached about 80 per cent of U.S. levels and stands about 10 per cent above the EU in 2024.

New analysis from the Clarivate Centre for Innovation in Regulatory Science (CIRS) shows that of the 38 new active substances approved by six major global regulators between 2019 and 2023, 66 per cent (25) have been approved in China and 18 per cent (7) remain under review by the National Medical Products Administration (NMPA). Among the four Class 1 innovative chemical drugs approved in China, sponsors submitted applications before first global approval, and the shortest interval between NMPA approval and first global approval was 334 days. Some biopharma companies are now filing in China first, or earlier in China than in Australia, Canada, Japan or Europe. These cases are limited but indicate that China is being incorporated earlier into global regulatory and commercial strategies.